Seattle Genetics Inc. (SGEN)

Trade SGEN now with
11/15/2018 8:04:24 AM Seattle Genetics: FDA Grants Breakthrough Therapy Designation To ADCETRIS For Frontline Peripheral T-Cell Lymphomas
11/14/2018 8:02:26 AM Seattle Genetics Begins Phase 1 Clinical Trial Of SEA-BCMA For Patients With Relapsed Or Refractory Multiple Myeloma
11/5/2018 8:02:31 AM Seattle Genetics Submits SBLA For ADCETRIS In Frontline Treatment Of CD30-Expressing Peripheral T-Cell Lymphomas
10/26/2018 8:02:35 AM Seattle Genetics Announces Multiple Data Presentations Of ADCETRIS In Patients With Hodgkin Lymphoma At ISHL 2018
10/25/2018 4:30:56 PM Seattle Genetics Q3 Loss/share $0.42 Vs. Profit $0.34 Year Ago
10/1/2018 6:47:57 AM Seattle Genetics, Takeda Report Positive Results From Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS
9/21/2018 10:52:12 AM Seattle Genetics Announces ADCETRIS Approval In Japan For Frontline Hodgkin Lymphoma
9/18/2018 4:07:42 PM BioClin Therapeutics Appoints Scott Myers As CEO
8/27/2018 8:31:51 AM Harpoon Therapeutics Appoints Scott Myers To Board
7/26/2018 4:04:22 PM Seattle Genetics Q2 EPS $0.47 Vs Loss $0.39 Last Year
7/12/2018 8:01:23 AM Seattle Genetics Announces First Patient Dosed In Phase 2 InnovaTV 207 Trial Of Tisotumab Vedotin
7/11/2018 8:02:02 AM Seattle Genetics Publishes Results From Two Tucatinib Phase 1b Clinical Trials In HER2-Positive Metastatic Breast Cancer
6/29/2018 10:22:26 AM Genmab To Pay Seattle Genetics Milestone Payment Of $7 Mln Under Antibody-Drug Conjugate Program Targeting AXL
6/26/2018 8:02:00 AM BioClin Therapeutics Appoints Scott Myers As Chairman
6/13/2018 8:02:37 AM Seattle Genetics Announces First Patient Dosed In Phase 2 Trial Of Tisotumab Vedotin